Novonesis to Acquire MicroBioGen, Boosting Industrial Yeast Capabilities

Novonesis has entered into an agreement to acquire Australian biotechnology company MicroBioGen, strengthening its capabilities in yeast technology and industrial fermentation. MicroBioGen specializes in the development of advanced yeast strains for industrial applications, with a particular focus on bioethanol production.

The planned acquisition builds on a long-standing relationship between the two companies. Novonesis first invested in MicroBioGen in 2013 and currently holds a 23% stake in the business. The transaction would bring the remaining ownership under Novonesis, expanding a collaboration that has continued for more than a decade.

Novonesis CEO Ester Baiget said the acquisition represents another step toward the company’s 2030 strategy. She highlighted the transaction’s role in strengthening the company’s yeast and research and development capabilities while maintaining a disciplined approach to investments designed to support long-term growth.

MicroBioGen brings extensive scientific expertise in yeast strain development and industrial biotechnology. Novonesis said the acquisition complements its existing capabilities in microbiology and industrial fermentation. As a pure-play biology company, Novonesis invests approximately 10% of its annual sales in innovation, supporting the development of biological solutions for industrial and commercial applications.

Claus Crone Fuglsang, Chief Scientific Officer at Novonesis, said MicroBioGen is a strong strategic fit because of the companies’ extensive collaboration. He added that integrating MicroBioGen’s technology into Novonesis will help the company expand its biological solutions and strengthen its ability to address evolving customer requirements.

The acquisition is also expected to provide continuity for MicroBioGen’s existing customers and business partners. Novonesis said it will continue supporting the company’s existing partnerships and collaborations during the transition.

Geoffrey Bell, CEO and Co-Founder of MicroBioGen, described the transaction as a strong fit for the company and its employees. He noted that the two businesses have worked closely together for more than 10 years, making Novonesis a natural home for MicroBioGen.

Financial terms of the transaction have not been disclosed. Completion remains subject to customary regulatory approvals, including approval from the Australian Competition and Consumer Commission (ACCC).

Impact on Chemical Commodity Prices

The deal should have a limited direct impact on chemical commodity prices in the near term because it is primarily a technology and biotechnology transaction rather than a major capacity expansion. However, stronger yeast technology could improve bioethanol fermentation efficiency and potentially support higher ethanol output from existing feedstocks. This could indirectly affect markets for ethanol, industrial enzymes, fermentation-related inputs, and bio-based chemicals over the longer term. If improved yeast strains significantly raise bioethanol productivity, increased ethanol availability could place modest downward pressure on ethanol prices, while stronger bio-based production could influence demand for competing petrochemical-derived products. Overall, the immediate price impact is expected to remain limited.